A bradykinin antagonist and a caspase inhibitor prevent severe pulmonary hypertension in a rat model.

@article{TarasevicieneStewart2002ABA,
  title={A bradykinin antagonist and a caspase inhibitor prevent severe pulmonary hypertension in a rat model.},
  author={Laimute Taraseviciene-Stewart and Lajos Gera and Peter Hirth and Norbert Felix Voelkel and Rubin M. Tuder and John M Stewart},
  journal={Canadian journal of physiology and pharmacology},
  year={2002},
  volume={80 4},
  pages={269-74}
}
Chronically hypoxic rats (exposed to 5000 m elevation for 3 weeks) develop pulmonary hypertension (PH) that is reversed upon return to normoxia and is blocked by bradykinin (BK) antagonist B9430 treatment (100 microg/kg s.c. three times per week). Treatment of rats with both the synthetic VEGF receptor-1/2 antagonist 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-indolin-2-one (SU5416) (200 mg/kg, single s.c. injection) and hypoxia (3 weeks) causes irreversible severe PH characterized by marked… CONTINUE READING